Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study

Journal of Alzheimer's Disease

Volumn 46, Issue 4, 2015, Pages 971-982

  Welt, Tobias ^a   Kulic, Luka ^a   Hoey, Sarah E ^a   McAfoose, Jordan ^a   Späni, Claudia ^a   Chadha, Antonella Santuccione ^c   Fisher, Abraham ^b   Nitsch, Roger M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^c Swiss Agency for Therapeutic Products   (Switzerland)

Author keywords

Alzheimer's disease; Amyloid ; A PP processing; A PP transgenic mice; Microdialysis; Muscarinic acetylcholine receptor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CEVIMELINE; DICYCLOVERINE; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC M1 RECEPTOR; PROTEIN KINASE C ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ACTIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; SECRETASE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VIVO STUDY; INFANT; INTERSTITIAL FLUID; INVESTIGATIVE PROCEDURES; MICRODIALYSIS; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; TRANSGENIC MOUSE; TREATMENT DURATION; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HIPPOCAMPUS; METABOLISM; NONPARAMETRIC TEST; PROCEDURES;

ACTINS; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; DICYCLOMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; MICRODIALYSIS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RECEPTOR, MUSCARINIC M1; STATISTICS, NONPARAMETRIC; THIOPHENES;

EID: 84937033585     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150152     Document Type: Article

References (56)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
2. Lichtenthaler SF (2011) alpha-secretase in Alzheimer's disease: Molecular identity, regulation and therapeutic potential. J Neurochem 116, 10-21.
3. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
4. Wess J, Eglen RM, Gautam D (2007) Muscarinic acetylcholine receptors: Mutant mice provide new insights for drug development. Nat Rev Drug Discov 6, 721-733.
5. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6, 51-58.
6. Nitsch RM, Slack BE, Farber SA, Borghesani PR, Schulz JG, Kim C, Felder CC, Growdon JH, Wurtman RJ (1993) Receptor-coupled amyloid precursor protein processing. Ann N Y Acad Sci 695, 122-127.
7. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
8. Cisse M, Braun U, Leitges M, Fisher A, Pages G, Checler F, Vincent B (2011) ERK1-independent alpha-secretase cut of beta-amyloid precursor protein via M1 muscarinic receptors and PKCalpha/epsilon. Mol Cell Neurosci 47, 223-232.
9. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM (2000) Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann N Y Acad Sci 920, 285-291.
10. Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Muller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10, 1-6.
11. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28, 10422-10433.
12. Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI (2010) Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci 30, 4190-4196.
13. Liskowsky W, Schliebs R (2006) Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24, 149-156.
14. Medeiros R, Kitazawa M, Caccamo A, Baglietto-Vargas D, Estrada-Hernandez T, Cribbs DH, Fisher A, LaFerla FM (2011) Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol 179, 980-991.
15. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH (2003) Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 54, 235-238.
16. Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T, Chen CP, Wong PT (2006) Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol Aging 27, 1216-1223.
17. Overk CR, Felder CC, Tu Y, Schober DA, Bales KR, Wuu J, Mufson EJ (2010) Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. J Chem Neuroanat 40, 63-70.
18. Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, Beach TG (2011) Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol 122, 49-60.
19. Tsang SW, Pomakian J, Marshall GA, Vinters HV, Cummings JL, Chen CP, Wong PT, Lai MK (2007) Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease. Neurobiol Aging 28, 1381-1387.
20. Ikin AF, Causevic M, Pedrini S, Benson LS, Buxbaum JD, Suzuki T, Lovestone S, Higashiyama S, Mustelin T, Burgoyne RD, Gandy S (2007) Evidence against roles for phorbol binding protein Munc13-1, ADAM adaptor Eve-1, or vesicle trafficking phosphoproteins Munc18 or NSF as phospho-state-sensitive modulators of phorbol/PKC-activated Alzheimer APP ectodomain shedding. Mol Neurodegener 2, 23.
21. Xu H, Greengard P, Gandy S (1995) Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem 270, 23243-23245.
22. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem 275, 2568-2575.
23. Cisse M, Duplan E, Guillot-Sestier MV, Rumigny J, Bauer C, Pages G, Orzechowski HD, Slack BE, Checler F, Vincent B (2011) The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein. J Biol Chem 286, 29192-29206.
24. Soond SM, Everson B, Riches DW, Murphy G (2005) ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci 118, 2371-2380.
25. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC (2009) Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 605, 53-56.
26. Reid PR, Bridges TM, Sheffler DJ, Cho HP, Lewis LM, Days E, Daniels JS, Jones CK, Niswender CM, Weaver CD, Conn PJ, Lindsley CW, Wood MR (2011) Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): The development of ML169, an MLPCN probe. Bioorg Med Chem Lett 21, 2697-2701.
27. Sams AG, Hentzer M, Mikkelsen GK, Larsen K, Bundgaard C, Plath N, Christoffersen CT, Bang-Andersen B (2010) Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylac etamide (LuAE51090): An allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. J Med Chem 53, 6386-6397.
28. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 29, 14271-14286.
29. Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, Eshhar N, Heldman E (1998) Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem 71, 2094-2103.
30. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A (2001) Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 905, 220-223.
31. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH (2000) The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48, 913-918.
32. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671-682.
33. Giachetti A, Giraldo E, Ladinsky H, Montagna E (1986) Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol 89, 83-90.
34. Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28, 1297-1306.
35. Paxinos G, Franklin KBJ (2008) The Mouse Brain in Stereo-taxic Coordinates, Elsevier Academic Press.
36. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23, 8844-8853.
37. Kulic L, McAfoose J, Welt T, Tackenberg C, Spani C, Wirth F, Finder V, Konietzko U, Giese M, Eckert A, Noriaki K, Shimizu T, Murakami K, Irie K, Rasool S, Glabe C, Hock C, Nitsch RM (2012) Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Abeta APP mutation. Transl Psychiatry 2, e183.
38. van Koppen CJ, Kaiser B (2003) Regulation of muscarinic acetylcholine receptor signaling. Pharmacol Ther 98, 197-220.
39. Elvang AB, Volbracht C, Pedersen LO, Jensen KG, Karlsson JJ, Larsen SA, Mork A, Stensbol TB, Bastlund JF (2009) Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem 110, 1377-1387.
40. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273, 27765-27767.
41. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 29, 3020-3032.
42. Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ (2002) alpha-and beta-secretase: Profound changes in Alzheimer's disease. Biochem Biophys Res Commun 299, 373-376.
43. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y (2004) Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA101, 3632-3637.
44. Jiang S, Wang Y, Ma Q, Hou H, Zhang X, Zhang YW (2012) M1 muscarinic acetylcholine receptor interacts with BACE1 and regulates its proteosomal degradation. Neurosci Lett 515, 125-130.
45. Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics 5, 433-442.
46. Fisher A (2012) Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: Perspectives and challenges in treatment of Alzheimer's disease. J Neurochem 120(Suppl 1), 22-33.
47. Kurumatani T, Fastbom J, Bonkale WL, Bogdanovic N, Winblad B, Ohm TG, Cowburn RF (1998) Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Res 796, 209-221.
48. Govoni S, Bergamaschi S, Racchi M, Battaini F, Binetti G, Bianchetti A, Trabucchi M (1993) Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients. Neurology 43, 2581-2586.
49. Van Huynh T, Cole G, Katzman R, Huang KP, Saitoh T (1989) Reduced protein kinase C immunoreactivity and altered protein phosphorylation in Alzheimer's disease fibroblasts. Arch Neurol 46, 1195-1199.
50. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL (2004) Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci USA101, 11141-11146.
51. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, Growdon JH, Selkoe DJ (1993) Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 268, 22959-22962.
52. Slack BE, Breu J, Petryniak MA, Srivastava K, Wurtman RJ (1995) Tyrosine phosphorylation-dependent stimulation of amyloid precursor protein secretion by the m3 muscarinic acetylcholine receptor. J Biol Chem 270, 8337-8344.
53. Mills J, Laurent Charest D, Lam F, Beyreuther K, Ida N, Pelech SL, Reiner PB (1997) Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 17, 9415-9422.
54. Kim C, Jang CH, Bang JH, Jung MW, Joo I, Kim SU, Mook-Jung I (2002) Amyloid precursor protein processing is separately regulated by protein kinase C and tyrosine kinase in human astrocytes. Neurosci Lett 324, 185-188.
55. Racchi M, Govoni S (1999) Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. Trends Pharmacol Sci 20, 418-423.
56. Slack BE (2000) The m3 muscarinic acetylcholine receptor is coupled to mitogen-activated protein kinase via protein kinase C and epidermal growth factor receptor kinase. Biochem J 348 Pt 2, 381-387.